Lataa...
Fibroblast growth factor 21 inhibition aggravates cardiac dysfunction in diabetic cardiomyopathy by improving lipid accumulation
Diabetic cardiomyopathy (DCM) is one of the major causes of morbidity and mortality in diabetic patients. Recent studies have demonstrated an increased level of fibroblast growth factor 21 (FGF21) in the plasma of DCM patients, and FGF21 has been proven to be a cardiovascular protector of the heart....
Tallennettuna:
| Julkaisussa: | Exp Ther Med |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
D.A. Spandidos
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5763648/ https://ncbi.nlm.nih.gov/pubmed/29375676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2017.5375 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|